Interestingly, in this series of NSCLC spine metastases, the OncoCast score was driven by a distinct genomic signature, primarily by MET amplification (selected in 100% of models) and RB1 mutation (selected in 99%); consistent with the prior analyses, STK11 was selected in 75% of models and KEAP1 in 94%. The gene discussed is MET; the disease is non-small cell lung carcinoma.